Global Footprint Aspire Bariatrics holds FDA approval and CE mark with commercial availability in the EU, Middle East, and New Zealand, signaling regulatory readiness for international expansion. Target opportunities include U.S. hospitals and GI centers, EU-based distributors, and MEA/NZ markets; pursue regulatory and distribution partnerships to accelerate adoption.

Competitive Differentiation The AspireAssist is positioned as a non-surgical weight loss option with reported best-in-class results among endoscopic procedures, supported by an RCT conducted across several institutions. This creates a compelling proposition for obesity clinics, bariatric and gastroenterology centers, and insurers seeking non-surgical solutions; tailor value props around safety, efficacy, and post-therapy support.

Growth Financing Recent debt financing and existing funding indicate capital available to scale commercial efforts, despite modest current revenue. Leverage this to explore joint funded market entry with distributors, training programs, and field service expansions aligned with channel partnerships.

Channel Readiness With regulatory approvals and international reach, Aspire Bariatrics appears poised for distributor and partner networks in multiple regions. Target hospital systems, GI clinics, and obesity treatment centers for distribution and training contracts, supported by partner friendly terms.

Digital Marketing A tech stack that includes analytics and video channels signals strong digital marketing capability. Use this to generate partner and patient leads, provide co marketing assets, and accelerate adoption through online education and demos.